Skip to main content

Change in PDL Status for Glucocorticoids, Inhaled Drug Class Effective May 6, 2025

Last updated on

On May 6, 2025, the Texas Health and Human Services Commission (HHSC) removed the non-preferred status from the authorized generic fluticasone HFA products on the preferred drug list (PDL) because of product shortages.

The manufacturers of brand-name Asmanex HFA (Organon) and QVAR RediHaler (Teva Pharmaceuticals) indicated that these shortages are the result of product backorders caused by distribution and manufacturing delays.

The non-preferred status has been removed from the following drugs:

National Drug Code (NDC)Drug Name
66993-0078-96Fluticasone Prop HFA 44 Mcg
66993-0079-96Fluticasone Prop HFA 110 Mcg
66993-0080-96Fluticasone Prop HFA 220 Mcg

These changes allow providers to prescribe the authorized generic fluticasone HFA products without requiring a PDL prior authorization. This helps ensure that clients can continue to access essential asthma-control medications. 

Email vdp-formulary@hhsc.state.tx.us with any questions.